Epidemiological studies have demonstrated that the variability of the clinical response to infection caused by Mycobacterium leprae is associated with host genetic factors. The present study investigated the frequency of human leukocyte antigen (HLA) class II (DRB1) alleles in patients with leprosy from São Luís, Maranhão, Brazil. A case-control study was performed in 85 individuals with leprosy and 85 healthy subjects. All samples were analysed via polymerase chain reaction-sequence specific oligonucleotide probes. The HLA-DRB1*16 allele showed a higher frequency in the group with leprosy [(9.41% vs. 4.12%) odds ratio (OR) = 2.41 95% confidence interval (CI) (0.96-6.08) p = 0.05], whereas the HLA-DRB1*11 allele was less frequent in the group with leprosy [(6.47% vs. 11.76%) OR = 0.51 95% CI (0.23-1.12) p = 0.09]. The frequency of HLA-DRB1* alleles between the control group and leprosy patient subgroups presenting different forms of the disease showed that the HLA-DRB1*16 (16.13% vs. 8.24%, OR = 4.10, CI = 1.27-13.27, p = 0.010) and HLA-DRB1*14 (5% vs. 3.53%, OR = 4.63, CI = 1.00-21.08, p = 0.032) alleles were significantly more frequent in patients with different clinical subtypes of leprosy. The sample size was a limitation in this study. Nevertheless, the results demonstrated the existence of a genetic susceptibility associated with the clinical forms of leprosy. The low frequency of the HLA-DRB1*11 allele should be further studied to investigate the possible protective effect of this allele.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0074-02762012000900022 | DOI Listing |
Trop Med Infect Dis
November 2024
Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Forécariah GPW7+V9G, Guinea.
This study analyzed the trend and factors associated with medical-surgical complications in patients discharged from leprosy multidrug therapy at the Centre Hospitalier Régional Spécialisé (CHRS), in Macenta, Republic of Guinea. This was a retro 2012 ( = 54) and 2013 ( = 35) and then a slight decrease between 2014 ( = 34) and 2017 ( = 26). From 2019 ( = 18) to 2021 ( = 1), a significant d spective study using routine secondary data from 2012 to 2021.
View Article and Find Full Text PDFBMC Health Serv Res
December 2024
USAID Program for Accelerated Control of TB in Karamoja Region (PACT- Karamoja), Moroto City, Uganda.
Background: The Karamoja subregion is a high TB burden pastoralist community that previously had limited access to public health services. We explored the community's perceptions towards TB to better understand how healthcare services should be structured to meet the needs of the persons with TB and their households.
Methods: From September to October 2022, we conducted 12 focus group discussions (FGDs) and interviewed 95 persons (48 community members and 47 health workers).
JMIR Mhealth Uhealth
December 2024
Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, 100 Foster Road, Athens, US.
Background: Directly observed therapy (DOT) is the standard for monitoring adherence for tuberculosis (TB) treatment. However, the implementation of DOT is difficult for patients and providers due to a lack of financial and human resources. Mounting evidence suggests that emerging digital adherence technologies like video directly observed therapy (VDOT) can serve as an option.
View Article and Find Full Text PDFArch Dermatol Res
December 2024
Department of Dermatology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Leprosy is a chronic infectious disease which mainly affects the skin, nasal mucosa, and peripheral nerves. The aim of this study was to compare between the efficacies of serum anti-phenolic glycolipid 1 (APGL-I) level versus slit skin smear (SSS) in diagnosis of leprosy. This study involved 58 leprosy cases who were clinically examined, slit-skin smears were taken from all at diagnosis from four sites and APGL-I levels were seroassayed using ELISA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!